ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1632

PET/CT-Based Distribution of Arterial Involvement and Its Association With Clinical Outcomes in Takayasu Arteriti

Tokio Katakura1, Tsuyoshi Shirai2, Kentaro Mori1, Mikihiro Takahashi1, Yuito Tanno3, Soshi Okazaki3, So Itoi3, Yosuke Hoshi3, Tomoaki Machiyama3, Yusho Ishii3, Hiroko Sato3 and Hiroshi Fujii3, 1Department of Rheumatology, Tohoku University Hospital, Sendai, Japan, 2Department of Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan, 3Department of Rheumatology, Tohoku University Hospital, Sendai

Meeting: ACR Convergence 2025

Keywords: Imaging, Takayasu.s arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1612–1632) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: PET/CT enables assessment of active vascular inflammation in Takayasu arteritis (TAK), which is often difficult to evaluate with conventional imaging. Although the distribution of affected arteries has been classified into patterns by both conventional imaging and PET/CT, its relationship with clinical outcomes remains unclear. This study aimed to evaluate the significance of PET/CT-based arterial involvement in treatment-naïve TAK and its association with relapse and cardiovascular events.

Methods: We conducted a retrospective study of patients with TAK who underwent PET/CT before treatment between 2010 and 2024. Hierarchical clustering was performed based on the distribution of affected arteries, with 18F-fluorodeoxyglucose uptake assessed by a four-grade visual scale; the score ≥1 was considered positive. Clinical characteristics and outcomes were compared across clusters. Relapse and large vessel events were defined according to the 2018 EULAR recommendations and analyzed using survival analysis. Longitudinal changes in PET/CT and clinical activity were evaluated in patients with post-treatment PET/CT. Continuous variables were expressed as medians with interquartile ranges.

Results: Thirty patients were included, with a follow-up of 4.8 years (1.4–9.9), age at diagnosis of 48 years (28–58), and 90% female. All met Japanese diagnostic criteria; 80% met the 2022 ACR/EULAR criteria. Numano’s classification based on CT was as follows; I, 2; II, 10; III, 3; V, 15. Relapse occurred in 12 patients (40%) with one major relapse; and large vessel events in nine patients (30%); aortic regurgitation, 2; aortic aneurysm, 5; aortic stenosis. 4; cardiovascular death, 1. Hierarchical clustering revealed three distinct patterns: (A) thoracic type (mainly thoracic aorta with less frequent branch involvement; 43%), (B) diffuse type (extensive involvement of the aorta and its branches; 30%), and (C) localized type (mainly branch lesions; 27%) (Figure 1). The proportion of type V was 78% in A, 38% in B, and 38% in C (p=0.35), indicating inconsistency between PET/CT and angiographic classifications. PET vascular activity scores were significantly different among clusters: 9 (7–13) in A, 15 (12–21) in B, and 3 (1–5) in C (p< 0.01). CRP levels were as follows; 3.1 (1.7–3.8), 3.4 (1.4–5.6), and 0.7 (0.1–7.1) mg/dL (p=0.28). Relapse rates were the highest in B (23%, 78%, and 25%, p=0.04), whereas large vessel events tended to occur more in A (46%, 22%, and 13%; p=0.09) (Figure 2). Numano's classification was not associated with relapse or large vessel events. Among 17 patients with repeated scans, PET/CT activity was observed despite clinical inactivity, indicating a risk of relapse in such patients. Meanwhile, a relapse was also observed in a patient whose PET/CT activity had normalized (Figure 3).

Conclusion: PET/CT-based arterial pattern in TAK was classified into three clusters with distinct prognostic profiles. Diffuse type was associated with higher relapse, whereas thoracic type tended to present vascular complications. Conventional angiographic classification failed to predict these outcomes, and thus PET/CT would provide superior risk stratification in TAK.

Supporting image 1Figure 1. Hierarchical clustering based on the distribution of affected arteries revealed three distinct patterns.

Supporting image 2Figure 2. Survival curve analysis showed higher relapse rates in the diffuse type and a trend toward more large vessel events in the thoracic type.

Supporting image 3Figure 3. Sankey diagram illustrating temporal changes in clinical and PET/CT disease activity.


Disclosures: T. Katakura: None; T. Shirai: AbbVie/Abbott, 6, Asahi Kasei, 6, Astellas, 6, AstraZeneca, 6, Chugai, 6, Eli Lilly, 6, GlaxoSmithKlein(GSK), 6, Novartis, 6, Pfizer, 6, Sanofi, 6; K. Mori: None; M. Takahashi: None; Y. Tanno: None; S. Okazaki: None; S. Itoi: None; Y. Hoshi: None; T. Machiyama: None; Y. Ishii: None; H. Sato: None; H. Fujii: None.

To cite this abstract in AMA style:

Katakura T, Shirai T, Mori K, Takahashi M, Tanno Y, Okazaki S, Itoi S, Hoshi Y, Machiyama T, Ishii Y, Sato H, Fujii H. PET/CT-Based Distribution of Arterial Involvement and Its Association With Clinical Outcomes in Takayasu Arteriti [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/pet-ct-based-distribution-of-arterial-involvement-and-its-association-with-clinical-outcomes-in-takayasu-arteriti/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pet-ct-based-distribution-of-arterial-involvement-and-its-association-with-clinical-outcomes-in-takayasu-arteriti/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology